ACCESS Newswire

BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities

Share

VANCOUVER, BC / ACCESS Newswire / January 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is excited to announce a major milestone in its research and development journey. The company is transitioning its cutting-edge R&D activities to the Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany, with operations scheduled to begin on March 1, 2025. This move underscores BioNxt's commitment to scientific innovation and advancing solutions for unmet medical needs.

The new laboratory facility provides BioNxt with access to cutting-edge technologies, an expanded 1,000-square-meter research environment, and strategic opportunities for scientific collaboration within Europe's biotech hub. The transition is expected to accelerate the company's ongoing projects, particularly in the areas of drug delivery systems, neurodegenerative disease therapeutics, and next-generation biomedical technologies.

BioNxt Relocates to Gen-Plus: Strategic Importance for Advanced R&D

By leveraging the advanced and innovative infrastructure of the Gen-Plus Laboratory, BioNxt aims to harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt to:

  • Enhance R&D Capabilities: With access to cutting-edge equipment and analytical tools, BioNxt is better positioned to develop innovative solutions and optimize its research outcomes.

  • Foster Collaborations: The Munich location enables proximity to leading research institutions, biotech firms, and academic experts, paving the way for impactful partnerships.

  • Accelerate Innovation: The advanced resources at Gen-Plus Laboratory allow BioNxt to streamline workflows and reduce the time to bring groundbreaking therapies to market.

"BioNxt's transition to Gen-Plus marks a pivotal moment for BioNxt," said Hugh Rogers, CEO of BioNxt Solutions Inc. "This transition is both strategic and timely, and unlocking new possibilities for added strength on IP with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide. We are thrilled about the opportunities that this new chapter brings, providing Impact on Current and Future projects."

BioNxt's innovative projects, including the development of advanced drug delivery systems such as sublingual thin films, transdermal patches, and other targeted therapeutic platforms, stand to gain significant advantages from the advanced capabilities at the Gen-Plus Laboratory. This cutting-edge facility is poised to accelerate preclinical research timelines, enhance formulation accuracy, and streamline the development of next-generation therapeutics.

About Gen-Plus GmbH & Co. KG

Gen-Plus GmbH & Co. KG, headquartered in Munich, Germany, is a premier Contract Research and Development Organization (CRDO) with over 25 years of experience in pharmaceutical formulation and development. The company operates a 1,000-square-meter state-of-the-art laboratory equipped for handling high-potency active pharmaceutical ingredients and licensed for GMP-compliant production, including narcotics.

Gen-Plus specializes in developing solid and semi-solid dosage forms, transdermal patches, and oral thin films, offering end-to-end services from feasibility studies to clinical trial supply production. The company leverages advanced technologies such as hot-melt extrusion, drug printing, and amorphization of APIs to deliver comprehensive pharmaceutical solutions.

Committed to innovation, Gen-Plus collaborates with leading European research institutions and biotech companies to drive advancements in pharmaceutical solutions. The company's expertise and cutting-edge infrastructure make it a trusted partner in accelerating drug development and commercialization.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.

With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.

Investor Relations & Media Contact

Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt

Cautionary Statement Regarding "Forward-Looking" Information

This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is based on management's expectations, estimates, projections, and assumptions as of the date of this press release. It is subject to significant risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, general economic conditions, market conditions, regulatory risks, technological advancements, and other factors described in the Company's public disclosure filings.

Readers are cautioned not to place undue reliance on forward-looking information, as actual outcomes may differ significantly from those expressed or implied, due to various factors beyond the Company's control. The Company undertakes no obligation to update or revise any forward-looking information, except as required by law.

SOURCE: BioNxt Solutions Inc.



View the original press release on ACCESS Newswire

BioNxt Solutions Inc.

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Registration Now Open for World of Coffee 2025 in Geneva: The Premier Event for Coffee Professionals6.2.2025 09:00:00 CET | Press release

Join Over 13,000 Attendees and 430+ Exhibitors at Europe's Largest Specialty Coffee Trade Show GENEVA, SWITZERLAND / ACCESS Newswire / February 6, 2025 / World of Coffee, the essential event for coffee professionals, enthusiasts, and innovators from around the globe will have a 2025 edition in Geneva, Switzerland, at the Palexpo SA, June 26-28. Following the record-breaking success of World of Coffee in Copenhagen, this flagship coffee trade show is set to welcome over 13,000 coffee professionals from 160+ countries for three days of business, networking, and education. Produced by the Specialty Coffee Association (SCA), the trade show and conference are proudly supported by Host Sponsor BTW Water + More; Platinum Sponsor Barista Attitude; Diamond Sponsor Nestlé Professional; and Gold Sponsor Alpro. Café de Colombia will be featured as the Portrait Country with unique cultural activations, and a pop-up café experience. "Geneva is the ideal location for hosting our flagship European tra

U.S.-Based Blockchain Kadena and Croatian Football Federation (HNS) Partner to Revolutionize Fan Engagement6.2.2025 09:00:00 CET | Press release

The Agreement Includes Regular Season Play as Well as the 2026 FIFA World Cup 2026 and UEFA EURO 2028 NEW YORK CITY, NEW YORK / ACCESS Newswire / February 6, 2025 / Kadena, the industry leader in scalable blockchain technology, and the Croatian Football Federation (HNS) have announced a groundbreaking partnership to provide a seamless digital fan engagement experience to Croatian national team fans. This partnership will encompass major global football events through 2028, including the 2026 FIFA World Cup and 2028 UEFA Euro Cup.Kadena and The Croatian Football Federation Enter Partnership to Revolutionize Fan Engagement This collaboration will introduce high-visibility activations, access to VIP experiences, and the migration of the HNS ERC-20 fan token, VATRENI, from Polygon to Kadena via the Kinesis Bridge. "The goal with the [VATRENI] token is to push the boundaries of traditional fan engagement opportunities of the past and introduce more of a future-focused fan experience. We're

Preservica Delivers Actionable Trusted Long-Term Data with New Innovations in AI and Active Digital Preservation6.2.2025 09:00:00 CET | Press release

BOSTON, MA AND OXFORD, UK / ACCESS Newswire / February 6, 2025 / Preservica, the industry leader in Active Digital Preservation™ archiving, today unveiled a series of groundbreaking innovations to its pioneering platform. These enhancements further simplify and automate the complex task of preserving critical long-term data, ensuring it remains instantly usable, reliable, and trusted for compliance and emerging AI use. With up to a third of digital content needing to be retained long-term (more than 7 years) according to IDC, unreadable or lost data from poor retention policies, obsolete file formats and accidental or intentional change or deletion is not only a serious compliance, reputational and legal risk but also impacts an organization's ability to leverage AI for value creation and process automation. "As digital content continues to rapidly grow in volume and complexity, having a robust and secure foundation of instantly useable, reliable and trusted long-term data has become a

Glenmorgan Investments On Track to Reach $7 Billion in Assets Under Management6.2.2025 08:00:00 CET | Press release

Glenmorgan Investments, a leading global investment firm, is excited to announce record capital inflows across both institutional and retail sectors in the first six weeks of 2025. LONDON, UNITED KINGDOM / ACCESS Newswire / February 6, 2025 / The company is on track to surpass $7 billion in assets under management (AUM) by the time it reports its Q1 2025 results, marking a significant milestone in its ongoing growth and success. These impressive inflows come as a direct result of the company's continued dedication to innovative investment strategies, which have garnered strong interest from both institutional investors and individual retail clients. Glenmorgan's diverse portfolio and commitment to delivering exceptional returns have been key drivers in attracting new capital during this record-breaking period. In particular, the company has experienced a significant surge in retail investor participation since the announcement that the highly sought-after Digital Asset Innovation Fund

KALEO Frontman JJ Julius Son and Entrepreneur Robert Wessman to Launch Unique Limited-Edition Wine Collection at WineParis6.2.2025 07:08:00 CET | Press release

An Icelandic Merger of Music and Winemaking SAINT-CERNIN-DE-LABARDE, DORDOGNE, FRANCE / ACCESS Newswire / February 6, 2025 / JJ Julius Son, acclaimed frontman for the internationally renowned blues-rock band KALEO, and entrepreneur Robert Wessman have joined forces, creating a limited-edition wine collection. This collaboration highlights their shared Icelandic heritage and promises to deliver an exquisite experience for wine enthusiasts and music lovers. The wines were created in the summer of 2024, by JJ and Robert, at the Maison Wessman winery in France, blending countless samples from barrels in the maison's cellar, under the supervision of oenologist Julien Viaud, of Michel Rolland and Associates. JJ and Robert will formally launch the collection on Feb. 10, 2025, at the global trade fair "WineParis." "We are excited to embark on this journey together," said Robert Wessman. "The goal is to create wines that not only delight the palate but also tell a story of friendship and collab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye